drugset / Trial / NCT01417026

Intranasal Oxytocin and Learning in Autism

NCT01417026

Phase 2 Completed 36 enrolled Robert Schultz
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The main objective of this study is to determine the safety and therapeutic potential of intranasal oxytocin in children and adolescents with autism spectrum disorder (ASD) when paired with a computer game intervention that is designed to enhance face perception skills.

Timeline

Start
2011-09
Primary completion
2015-04
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Oxytocin Peptide 24 iu Intranasal